BioSpace News Archive

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present virtually at the JMP Securities Hematology & Oncology Summit on Wednesday, December 7, 2022, at 11:40 a.m. ET.

First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”) announced today that it has selected the initial clinical trial sites for its planned Phase 2 clinical trial to evaluate an enhanced enteric microgranule delivery formulation of adrulipase as a treatment for exocrine pancreatic insufficiency.

BioRestorative Therapies, Inc.(“BioRestorative” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced an agreement with Regenexx, LLC pursuant to which the license rights granted by Regenexx to the Company for intellectual property developed to address chronic lumbar disc disease have been made exclusive.

Jeune Aesthetics, Inc., a wholly owned subsidiary of Krystal Biotech, Inc. announced that the company will participate in the investor-focused Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference, which is taking place in Miami on December 8.

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, today announced positive updated data from its Phase 1 dose escalation study of NKX019 as monotherapy to treat patients with relapsed or refractory (r/r) non-Hodgkin lymphoma (NHL).

Lynk Pharmaceuticals Co., Ltd. announced that it has dosed the first patient in a Phase II clinical trial of its innovative drug LNK01003 in Ulcerative Colitis (UC).

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) and Incyte (Nasdaq: INCY) today announced that results from the Phase 1/2 trial of axatilimab, Syndax’s anti-CSF-1R antibody, in patients with recurrent or refractory chronic graft-versus-host disease (cGVHD) following two or more prior lines of therapy, were published in the Journal of Clinical Oncology.

IceCure Medical Ltd. today reported financial results as of and for the nine months ended September 30, 2022 and operational and commercial highlights for the third quarter.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that John Higgins has retired as Chief Executive Officer, effective as of today, and that the company’s board of directors has named Todd C. Davis as Chief Executive Officer.

Athira Pharma, Inc. today presented data highlighting the potential therapeutic benefits of ATH-1105, a small molecule positive modulator of the HGF/MET neurotrophic system, in a preclinical mouse model of amyotrophic lateral sclerosis (ALS).